Expanded Indication News Today

Hepatitis Awareness Month is designed to raise awareness of viral hepatitis and promote testing and vaccination while decreasing the stigma against the virus.

Fourth-Quarter and Full-Year Sales Reflect Sustained Growth Across Oncology and Vaccines Fourth-Quarter Worldwide Sales Were $14.6 Billion, an Increase of 6% From Fourth Quarter 2022; Excluding...

SI-Bone earned FDA 510(k) clearance of the iFuse Bedrock Granite implant system in a smaller diameter, according to a Jan. 30 news release. 

/PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today...

First International Approval for Expanded Indication and Certification for MT Cap and D-Tect™ TechnologiesMALVERN, Pa., July 17, 2023 -- Neuronetics, Inc. , a medical technology company focused...

Amgen Inc.’s treatment Otezla was approved by the U.S. Food and Drug Administration to treat adults with all levels of plaque psoriasis.

(2) NEW YORK CITY (dpa-AFX) - Todays Daily Dose brings you news about KemPharm scoring regulatory nod for its ADHD drug, expanded FDA approval for Pfizers Lorbrena, United Therapeutics scrapping the development of Trevyent, Vir Biotechnology closing the enrollment in VIR-7831 arm of ACTIV-3 trial, and Takeda securing global rights to Ovids investigational medicine Soticlestat. Read on. 1.KemPharm Scores FDA Nod For ADHD Drug KemPharm Inc. (KMPH) soared more than 42% on Wednesday, following FD...

Share this article Share this article ResearchAndMarkets.coms offering. In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global IV and Oral Iron Drugs Market Report The global IV and oral iron drugs market by revenue is expected to grow at a CAGR of 11.6% during the period 2021-2026. The global IV and oral iron drugs market is expected to grow due to the prevalence of iron deficiency (ID). This deficiency is a highly widespread nutritional disorder, affectin...